SCHEMBL103209

SCHEMBL103209

N/C(Cc1ccccc1F)=N\O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TAAR1 Q96RJ0 3/20 0.47
IDO1 P14902 2/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPK8 P45983 1/20 0.41
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.39
MAOB P27338 1/20 0.39
PARP15 Q460N3 1/20 0.39
PARP14 Q460N5 1/20 0.39
PARP10 Q53GL7 1/20 0.39
AOC3 Q16853 1/20 0.39
USP2 O75604 1/20 0.38
KDM1A O60341 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103210 1.00 LMNA (0.56) LMNASMN1; SMN2TAAR1IDO1ALDH1A1
SCHEMBL10263865 0.78 LMNA (0.41) LMNASMN1; SMN2TAAR1ALDH1A1MAPK8
SCHEMBL837844 0.78 LMNA (0.41) LMNASMN1; SMN2TAAR1ALDH1A1MAPK8
SCHEMBL21729219 0.77 IDO1 (0.47) LMNASMN1; SMN2IDO1ALDH1A1MAPK8
SCHEMBL836281 0.77 LMNA (0.49) LMNASMN1; SMN2IDO1ALDH1A1MAPK8
SCHEMBL21729165 0.77 LMNA (0.53) LMNASMN1; SMN2IDO1ALDH1A1MAOB
SCHEMBL874094 0.77 LMNA (0.49) LMNASMN1; SMN2IDO1ALDH1A1MAPK8
SCHEMBL641850 0.76 PKM (0.60) LMNASMN1; SMN2TAAR1IDO1MAPK8
SCHEMBL102788 0.76 LMNA (0.61) LMNASMN1; SMN2TAAR1ALDH1A1MAPK8
SCHEMBL102787 0.76 LMNA (0.61) LMNASMN1; SMN2TAAR1ALDH1A1MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 US disclosed
US-8883826-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-11-11 US disclosed
US-8674106-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-03-18 US disclosed
US-20130245355-A1 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS MERCK PATENT GMBH (DE) 2013-09-19 US disclosed
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-07-11 US disclosed
WO-2012164085-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-12-06 WO disclosed
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2012-11-01 US disclosed
WO-2012072200-A1 3-HETARYL-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS MERCK PATENT GMBH (DE) 2012-06-07 WO disclosed
EP-2426115-A2 Alkynyl derivatives as modulators of metabotropic glutamate receptors Addex Pharma SA (CH) 2012-03-07 EP disclosed
US-8101637-B2 Alkynyl derivatives as modulators of metatropic glutamate receptors ADDEX PHARMA SA (CH) 2012-01-24 US disclosed
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2009-05-14 US disclosed
EP-1765795-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharmaceuticals SA (CH) 2007-03-28 EP disclosed
WO-2005123703-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 LMNA 4407/4885SMN1; SMN2 881/4885TAAR1 139/4885
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS P2RY1, P2RX1, P2RX3 LMNA 2079/4885SMN1; SMN2 2968/4885TAAR1 240/4885
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS GRM5, GRM2, GRM1 LMNA 4715/4885SMN1; SMN2 1094/4885TAAR1 143/4885
US-20130245355-A1 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS PDK1, PDK2, PDK3 LMNA 3634/4885SMN1; SMN2 4203/4885TAAR1 4133/4885
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 LMNA 4407/4885SMN1; SMN2 881/4885TAAR1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.